鋭明技術(002970.SZ):第二期員工持股計劃非交易過户完成
格隆匯8月6日丨鋭明技術(002970.SZ)公佈,公司於2024年8月6日收到中國證券登記結算有限責任公司深圳分公司出具的《證券過户登記確認書》,公司回購股份專用證券賬户所持有的104.00萬股標的股票(佔公司截至2024年7月31日總股本的0.5949%)已於2024年8月5日通過非交易過户形式過户至“深圳市鋭明技術股份有限公司-第二期員工持股計劃”專用證券賬户,過户價格為12.71元/股。
本次員工持股計劃的存續期為36個月,自本次員工持股計劃草案經公司股東大會審議通過且公司公吿最後一筆標的股票過户至本次員工持股計劃名下之日起計算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.